CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 56 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Cincinnati, Ohio, United States and 43 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Cincinnati, Ohio, United States and 110 other locations
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....
Phase 1, Phase 2
Cincinnati, Ohio, United States and 35 other locations
of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...
Phase 3
Cincinnati, Ohio, United States of America and 120 other locations
of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed ...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 34 other locations
trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia...
Phase 1, Phase 2
Cincinnati, Ohio, United States of America and 2 other locations
with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when g...
Phase 3
Cincinnati, Ohio, United States and 164 other locations
The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 24 other locations
This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orall...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 44 other locations
Clinical trials
Research sites
Resources
Legal